cyrilzakka/clinical-trials huggingface dataset:
Dual Tasking in Children With Cerebral Palsy and Healthy Children: an EEG Study

Simultaneous execution of motor and cognitive tasks is embedded in the daily life of children. An EEG study will be conducted on healthy children and children with cerebral palsy to study the neural correlates during dual tasking while walking

Children will walk at their preferred speed on a treadmill. During dual tasking, they will listen to animals cries and will have to count the number of specified animals cries.

Eligibility Criteria:
Inclusion Criteria:

* normal walking

For children with cerebral palsy: diplegia or hemiplegia, GMFCS 1 or 2, no botulinium injection since 4 months

Exclusion Criteria:

* medical problem
Exercise with Audible Cues on Motor Unit Behavior in Athletes with Anterior Cruciate Ligament Reconstruction

The closed kinetic chain (CKC) of terminal knee extension exercise (TKE) is designed to activate VM activity for knee injury training. This CKC exercise is effective for highest recruiting muscle activity, especially safe for post-operative knee surgery. The study of ACL reconstruction rehabilitation guideline suggests that exercises can be applied within the early phase of rehabilitation to prevent knee laxity and less knee pain compared to open chain exercise. Therefore, it is interesting to investigate the effects of TKE exercise synchronized with metronome pace on change of VM motor unit behavior in post operative ACL reconstruction. This study focuses on the immediate effect of 1-seesion TKE and expects that adding metronome during TKE will enhance neuromuscular control of VM and may change motor unit behavior.

This study investigates the effect of exercise with sensory integration technique on neuromuscular control in athletes with anterior cruciate ligament reconstruction.

Eligibility Criteria:
Inclusion Criteria:

* Male or female participants who receive primary ACL reconstruction within 2 weeks with or without meniscus repair
* No or mild resting pain (Numeric rating scale ≤ 3)
* Reconstruction procedures using autograft including hamstrings or bone-patella bone grafts
* Age range 18-35 years (33).
* BMI of 18.5-25 kg/m² (34).
* Tegner activity scale ≥ level 4

Exclusion Criteria:

* Non-weight bearing within 2 weeks after the operation (prescription from surgeon)
* Hearing problem, such as being unable to hear the metronome sound or being unable to synchronize exercises with the metronome correctly
* Limitations in knee extension range caused by joint stiffness evaluated by using passive knee range of motion
* Unable to perform active and passive ≥ 30º knee flexion on the operative side
* History of serious injury or operation of lower back and lower extremities such as fracture
* Lower back or lower extremities pain within 6 months before the study
* On the pain killer medication
The Broken Heart Study II (BHS-II)

The goals of this study are as follows:

1. To rigorously establish and characterize heterogeneity in the pathophysiology of Takotsubo Syndrome (TS).
2. To rigorously test the contribution of TS triggering events and mental stress responsiveness to 1-year prognosis after TS event.

Newly admitted patients with a validated diagnosis of Takotsubo Syndrome (TS; n=106) will be enrolled from 3 large medical centers in the Providence, Rhode Island area. Between 2 and 4 weeks after discharge, clinically stable patients will undergo an in-person comprehensive interview to identify the events proximal to the onset of TS symptoms, complete a battery of psychosocial questionnaires and undergo a validated laboratory stress protocol. Baseline and reactive changes in measures of autonomic nervous system activity (epinephrine and norepinephrine - primary outcome), and in the secondary outcomes of cardiac vagal control and left ventricular function (ejection fraction; regional and global longitudinal strain assessed with speckle tracking echocardiography) will be assessed. Echocardiographic evaluations will be repeated 12 months thereafter together with information on major adverse cerebrovascular events.

Eligibility Criteria:
Inclusion Criteria:

* Age \>=18
* A new diagnosis of takotsubo syndrome fulfilling Mayo Clinic criteria
* Ability to understand and speak English

Exclusion Criteria:

* Inability or unwillingness to give informed consent
* Severe cognitive impairment
* Uncontrolled hypertension
* Acute psychosis
* High suicidal risk
* Pregnancy
* Poor echocardiographic window
* Conditions that would interfere with adherence to study requirements (e.g., ongoing alcohol or substance abuse)
* If the participant is clinically unstable
Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

To determine the safety and efficacy of the combination of Etanercept and Docetaxel in patients with advanced solid tumors for which there is no standard treatment.


Eligibility Criteria:
Inclusion Criteria:

* Must have pathologically or cytologically confirmed advanced solid malignancy for which there is no standard treatment exists.
* Solid malignancy that has persisted or recurred following prior therapy or advanced solid malignancy for which docetaxel is considered an acceptable first line treatment option:

  * Non-Small Cell Lung
  * Breast
  * Head and Neck
  * Esophageal
  * Stomach
  * Ovarian carcinomas
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
* Life expectancy of at least 12 weeks.
* Must have adequate organ function
* Peripheral Neuropathy must be less than Grade 2
Noninvasive Diagnosis Model for High-risk Varices in Cirrhosis

This is an observational ambispective cohort study to validate the Baveno VI guideline and develop a new diagnostic model to screen high-risk varices (HRV) of liver cirrhosis using iLivTouch.

Esophageal variceal bleeding is a common and fatal complication in patients with liver cirrhosis. The diagnosis of high-risk varices (HRV) traditionally depends on gastroscopy, which is expensive and poorly tolerated with patients. Baveno VI guideline has put forward a HRV screening model based on liver stiffness and platelet count. This is an observational ambispective cohort study. The retrospective cohort is derived from the previous records of the hospital information system, and the prospective cohort is enrolled prospectively at the local research center when participants meet the inclusion criteria. The purpose of this study is to establish a diagnostic model of HRV in patients with liver cirrhosis according to the liver stiffness value measured by iLivTouch and other laboratory indexes, so as to verify the applicability of Baveno VI standard under the condition of iLivTouch and establish a cutoff value that is more suitable for iLivTouch. In addition, this study will try to find some new indexes to further improve the diagnostic efficiency of HRV. The minimum enrolment period is anticipated to be 6 months per center and will be extended if necessary to reach the overall study target.

Eligibility Criteria:
Inclusion Criteria:

1. Age 18-75;
2. Patients with liver cirrhosis diagnosed by clinical or imaging diagnosis;
3. The interval of iLivTouch and esophagogastroduodenoscopy is no more than 3 months;

Exclusion Criteria:

1. the interval between esophagogastroduodenoscopy and iLivTouch is more than 3 months;
2. any decompensation events (ascites, hepatic encephalopathy or gastroesophageal variceal bleeding) during endoscopy or iLivTouch examination, or during the interval between them;
3. currently taking nonselective beta blocker/ antiplatelet / anticoagulant drugs;
4. hepatocellular carcinoma;
5. after transjugular intrahepatic portosystemic shunt surgery;
6. after liver transplantation.
7. portal-spleen-mesenteric venous thrombosis;
8. patients with splenectomy;
9. BMI ≥ 30;
10. patients with acute active hepatitis or patients with cholestatic hepatitis;
11. IQR/median of liver stiffness measurement \> 30%.
Rehabilitation of People With Post-tuberculosis Lung Disease

Tuberculosis (TB) can leave numerous sequelae, where survivors experience a transition from an acute illness to living with a multifaceted chronic illness. Post-TB lung disease (PD-PTB) encompasses lung diseases and pathologies that occur after one or more episodes of TB, which can affect the patient's lung health and cause disabling symptoms that strongly affect their long-term health. In 2020, it was estimated that there were 155 million TB survivors still alive worldwide, with a large proportion of them carrying functional sequelae with profound socioeconomic repercussions. Thus, the aim of this study is to evaluate the effect of pulmonary rehabilitation (PR) on functionality and health-related quality of life (HRQoL) of people with PD-PTB and to build a PD-PTB severity scoring system based on the data. of pre-RP individuals using artificial intelligence technique.

Tuberculosis (TB) can leave numerous sequelae, where survivors experience a transition from an acute illness to living with a multifaceted chronic illness. Post-TB lung disease (PD-PTB) encompasses lung diseases and pathologies that occur after one or more episodes of TB, which can affect the patient's lung health and cause disabling symptoms that strongly affect their long-term health. In 2020, it was estimated that there were 155 million TB survivors still alive worldwide, with a large proportion of them carrying functional sequelae with profound socioeconomic repercussions. Thus, the aim of this study is to evaluate the effect of pulmonary rehabilitation (PR) on functionality and health-related quality of life (HRQoL) of people with PD-PTB and to build a PD-PTB severity scoring system based on the data. of pre-RP individuals using artificial intelligence technique. This is a randomized controlled trial, in which the sample will be divided into two groups: intervention for 12 weeks with PR and standard care. Functional capacity will be evaluated pre- and post-PR through the Glittre-ADL test with incorporation of dynamic ventilation, lung function (including impulse oscillometry), respiratory and peripheral muscle function, general fatigue and HRQoL. It is expected that PTB-PD patients will benefit significantly and, therefore, be able to (re)enter society, especially in job market.

Eligibility Criteria:
Inclusion Criteria:

* Patients with post-tuberculosis lung disease, clinically stable and able to perform \>80% of training sessions.

Exclusion Criteria:

* Presence of comorbidities not related to PD-PTB.
* Patients with inability to perform TGlittre.
* Patients who have cognitive changes that impair their inclusion in the study.
* Treatment abandonment during the application of the PR protocol.
* Uncontrolled hypertension or use of psychotropic medications.
* Any significant limitations due to osteoarthropathy.
* Having had any orthopedic surgery in the previous year.
Effect of Lipikar Urea 30% Before Actinic Keratoses Treatment

This study is conducted in one center in Germany, in adult subjects having actinic keratoses (grade I or II) lesions on the scalp and meeting specific inclusion/exclusion criteria. The purpose of the study is to evaluate a holistic management (efficacy, tolerability and lesion cosmetic outcomes) of Tolak® treatment.

Actinic keratoses (AK) are chronic skin changes usually induced by UV radiation. There are numerous options to treat AK. Some of the most used field-directed therapies include topical therapy with 5-fluorouracil (5-FU) cream and photodynamic therapy. However, the treatment with 5-FU is not without side effects (erythema, pruritus, itching/burning, etc.). Therefore, in daily clinical practice, cosmetic pre- and concomitant applications of cosmetics are often recommended to increase the efficacy as well as the tolerability of Tolak®.

The aim of this randomized, evaluator blinded, controlled parallel group study conducted in compliance with the 2013 version of the Declaration of Helsinki is to determine whether and how the application of cosmetics leads to an influence on the microbiome of AK.

Statistical method: The variables will be analyzed by using the Cochran-Mantel-Haenszel (CMH) statistic, after ridit transformation with the row mean difference statistics, testing the hypothesis of equality. Each test will be two-sided, at the 0.050 significance level.

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of at least 4 non-hypertrophic, non-hyperkeratotic actinic keratosis of the the scalp
* planned treatment of actinic keratoses of the scalp with Tolak®
* Olsen grade I or II

Exclusion Criteria:

* known or documented intolerance to any of the ingredients of Tolak® or Lipikar Urea 30%
* treatment of actinic keratoses in the treatment area within the past 3 months (e.g. photodynamic therapy, topical 5-FU, diclofenac, imiquimod, cryotherapy etc.)
* suspected invasive squamous cell cancer in the treatment area
* chronic wounds, erosions, pre-existing inflamed or infected skin with disruption of the epidermal barrier in the treatment area current or within the last 8 weeks given systemic cancer medication or systemic treatment with 5-Fluorouracil
Quiet Eye Duration in Baseball

The purpose of this study is to measure the gaze movements of individuals as they watch videos of a baseball pitcher throwing pitches. The goal will be to determine whether there is an anticipatory movement to the location where the ball is released, and whether this anticipatory movement occurs in experienced baseball players more commonly than in inexperienced players.

20 subjects between 18 and 40 years of age (males and females) will participate. 10 subjects will be required to have experience in baseball or softball at the high school level or above within the last 10 years. A further 10 subjects will be recruited who did not have baseball experience at or above the high school level. Upon entering the laboratory, the experiment will be explained to the subjects. Subjects will be consented. Then, the subject's visual acuity and stereoacuity (depth perception) will be measured.

If subjects continue on to the experiment, they will also be asked to complete a short survey on previous baseball experience.

Subjects will stand in a batting stance facing a projector screen. They will then participate in trials in which they mimic batting a ball thrown by a pitcher. Six different pitch videos will be shown. The subjects will act as if they are batting the ball (no bat swing will occur) for each video. The movement of the subject's eye will be tracked using an eye tracker.

Eligibility Criteria:
Inclusion Criteria:

* 20/20 visual acuity in each eye Stereoacuity of 40 arc seconds are better

Exclusion Criteria:

* 20/25 or worse visual acuity in either eye Stereoacuity less than 40 arc seconds
Does Preoperative Pain Medication Management Influence Surgical Outcomes in Spinal Fusion

In light of the current opioid epidemic, there is an urgent need to address chronic opioid use prior to surgery before it is exacerbated by postoperative surgical pain. Our central hypothesis is that patients who taper their opioid use prior to surgery will have reduced postoperative opioid and pain medication usage, less postoperative pain, and improved patient reported outcomes relative to patients that do not taper prior to surgery. Our specific aims include: 1. Determine whether reducing patients' preoperative opioid usage through a structured tapering regimen reduces postoperative opioid and pain medication use. 2. Examine whether reducing patients' preoperative opioid usage through a structured tapering regimen reduces postoperative pain. 3. Determine whether reducing patients' preoperative opioid usage through a structured tapering regimen improves patient reported outcomes.


Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Indicated for lumbar, lumbosacral, or thoracolumbar spinal fusion surgery in the departments of Orthopedic Surgery and Neurosurgery
* Daily opioid use for at least 4 weeks prior to the preoperative planning appointment

Exclusion Criteria:

* Suboxone (buprenorphine) use
* Unable to complete patient reported outcome measures (PROMs)
Evaluate Marginal B. Loss in Immediate Implant Placement in Maxillary Esthetic Zone Using Socket Shield Versus Xenograft

Anterior maxilla (Esthetic zone) is very challenging area because of thin buccal plate of bone. After tooth extraction physiological process occur causing alteration of bone and soft tissue so, delayed placement of implant lead to loss of bone height and width. Immediate placement of implant is become essential to preserve the bone and soft tissue from loss.

Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket. This technique allow preservation of buccal plate of bone and soft tissue with minimum loss allowing better result in esthetic zone.


Eligibility Criteria:
Inclusion Criteria:

* Patients with badly broken teeth in upper esthetic zone with intact periodontal condition indicated for extraction, presence of at least 4 mm of bone beyond the root apex to guarantee implant primary stability, implant placement within the alveoli confines.
* Both sexes.
* No intraoral soft and hard tissue pathology.
* Physically able to tolerate conventional surgical and restorative procedures.
* Signing of an informed consent form.

Exclusion Criteria:

* Presence of fenestrations or dehiscence of the residual bony walls after extraction.
* Heavy smokers more than 20 cigarettes per day .(24)
* Patients with systemic disease that may affect normal healing e.g. uncontrolled diabetes.
* Psychiatric problems e.g. severe bruxism.
* Disorders to implant are related to history of radiation therapy to the head and neck neoplasia, or bone augmentation to implant site.
* Active infection in the teeth to be treated
* Vertical root fractures with displacement in the teeth of the surgical area
Evaluation of the Threshold for the Interpretation of the Results of a Method for the Blood Determination of Phosphatidyléthanol

For an analytical validation of the method for the determination of blood hosphatidylethathanol, it is necessary to:

* to compare the results of chronic and excessive ethanol patients with the cut-off proposed in the literature.
* Also assess the stability of phosphatidylethanol in total blood collected, and in blotted dried blood stains (DBS), depending on temperature (ambient temperature and +4°C)


Eligibility Criteria:
Inclusion Criteria:

* Person with alcohol consumption ≥ 40g/day (women) and ≥ 60g/day (men) according to WHO criteria
* Person hospitalized for a hospital withdrawal in the addiction service of Lille's hospital, without other distinctions.

Exclusion Criteria:

* Patient opposing the use of their personal data in the study
* Patient subject to protective measures (guardianship or curatorship)
* Person deprived of liberty
Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2

The response to vaccination for hepatitis is reduced in patients with HIV infection. The hypothesis of the study is that adjuvant interleukin-2 administered subcutaneously at the time of vaccination improves the response rate.


Eligibility Criteria:
Inclusion Criteria:

* Adults with stable antiretroviral therapy and negative for hepatitis A or B

Exclusion Criteria:

* Prior hepatitis A or B
the Effect of Tracleer on Tourniquet-associated Hypertension

Tourniquet is widely used in orthopedic surgery. However, prolonged tourniquet inflation may cause a gradual rise in blood pressure, which named as tourniquet-associated hypertension. Thus, to effectively prevent the tourniquet related hemodynamic responses is important for patients receiving limb surgery.

Tracleer is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. Tracleer can also be used to treat retistant hypertension. At present trial, the investigators are going to investigate the effect of Tracleer on tourniquet-associated hypertension during total knee arthroplasty.

At present study, the investigators will use endothelin receptor antagonist, Tracleer (Bosentan), to investigate the effect of Tracleer on tourniquet-associated hypertension during unilateral total knee arthroplasty, and evaluate its safety and effectivity. The purpose of this study is to find a new therapy to prevent and treat tourniquet-associated hypertension.

Eligibility Criteria:
Inclusion Criteria:

* Patients underwent selected total knee arthroplasty under general anesthesia
* ASA II-III
* 18\~65 years old
* Signed informed consent voluntarily

Exclusion Criteria:

* Do not apply tourniquet during the surgery
* Patients underwent emergency surgery
* Having applied tourniquet in last three months
* Patients underwent bilateral total knee arthroplasty
* Dysfunction of liver or kidney
* Anemia (Hb \<90 g/L)
* Serious myocardial disease (eg. coronary heart disease, heart failure, severe arrhythmia)
* Coagulation disorder
* Diabetic
* Leukocyte higher than normal value
* Pneumonia, asthma, chronic obstructive pulmonary disease
* Hypotension before surgery (systolic pressure \< 90 mmHg)
* Pregnant woman or puerpera
* Having being enrolled in other clinical trial in last 3 months
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects

Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed), and overall survival.


Eligibility Criteria:
Inclusion Criteria:

* Histologically and/or cytologically confirmed to have advanced renal cell carcinoma (RCC)
* Majority component of conventional clear-cell type is mandatory
* At least 1 measurable lesion (per RECIST)

Exclusion Criteria:

* Prior systemic treatment for RCC
* Evidence of current or prior central nervous system (CNS) metastases
* Cardiovascular disease
* Pregnant or nursing women
* Additional criteria applies
Comparison of IV Nalbuphine Versus Ibuprofen for Postoperative Pain Control in Cesarean Section

The local data is insufficient to directly compare IV nalbuphine versus ibuprofen among people in this region. The findings of this study would add to the existing data and would be helpful for health providers to opt for a better option for postoperative pain relief following a cesarean section under general anesthesia.


Eligibility Criteria:
Inclusion Criteria:

* Parturient females
* Aged between 18-45 years
* Gestational age above 32 weeks
* ASA class I to II
* Anticipated hospital stay for at least 24 hours

Exclusion Criteria:

* Known allergy to the drugs being evaluated in this study
* Renal and/or hepatic impairment (as per medical record)
* History of bronchial asthma or history or risk of intracranial hemorrhage (as per medical record)
* Low platelets count (\&lt;70000) or with bleeding diathesis
* BMI above 30 kg/m2